title: Orbital floor triamcinolone causing Cushing's syndrome in a patient treated with Kaletra for HIV 1.
abstract: We report the first known case of iatrogenic cushingoid features following orbital floor triamcinolone, a synthetic corticosteroid, in a patient taking Kaletra (200 mg lopinavir/50 mg ritonavir) twice daily and Truvada (tenofovir/emtricitabine) once daily for HIV 1. Previous reports have included similar findings following epidural triamcinolone injections and with inhaled fluticasone.
authors: Medical Eye Unit,  GSTT, London,  UK.
authors: Hannah Zelie Ruth
authors: HZ
authors: McConkey
authors: Helen
authors: H
authors: Williams
authors: Ranjababu
authors: R
authors: Kulasegaram
authors: Elizabeth
authors: E
authors: Graham
mesh_terms: D000328:Adult; D003480:Cushing Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D003937:Diagnosis, Differential; D004338:Drug Combinations; D004347:Drug Interactions; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D007267:Injections; D061466:Lopinavir / Q000627:therapeutic use*; D009915:Orbit; D019438:Ritonavir / Q000627:therapeutic use*; D041623:Tomography, Optical Coherence; D014221:Triamcinolone / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D004338:Drug Combinations; D005938:Glucocorticoids; C558899:lopinavir-ritonavir drug combination; D014221:Triamcinolone; D061466:Lopinavir; D019438:Ritonavir